Tiragolumab/Atezolizumab Drug Due Diligence Report 2026

This Tiragolumab/Atezolizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

148

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Tiragolumab/Atezolizumab can convert its Monoclonal antibody profile and PDL1 x TIGIT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tiragolumab/Atezolizumab (query alias: Tiragolumab/Atezolizumab)
Modality / target	Monoclonal antibody; PDL1 x TIGIT; PDL1 inhibitors, TIGIT inhibitors
Highest global status	Phase 2
Originator	F. Hoffmann-La Roche Ltd.
Active developers	F. Hoffmann-La Roche Ltd., Genentech, Inc., Roche China Holding Ltd.

The MCP disease footprint includes PD-L1 positive Solid Tumors, Recurrent Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06784947	Phase 2	Active, not recruiting	13	Objective Response Rate (ORR)
NCT06754501	Phase 2	Active, not recruiting	4	Safety and Adverse Events (AEs)
NCT07038915	Phase 2	Withdrawn	Not disclosed	Safety and adverse events (AEs).

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Phase 3; n=56; evaluation: not stated. Reported fields: Number of Participants With Adverse Events (AEs) = 26 Participants ; Number of Participants With Adverse Events (AEs) = 21 Participants ; -

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation

Phase 3; n=829; evaluation: not stated. Reported fields: Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)(Median): Hazard Ratio (HR) = 0.96(95% CI, 0.75 - 1.23), P-Value = 0.7586; Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)(Median) = 19.35 months (95% Confidence Interval, 13.80 - 29.47); Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)(Median): Hazard Ratio (HR) = 0.96(95% CI, 0.75 - 1.23), P-Value = 0.7586

A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Phase 2/3; n=542; evaluation: not stated. Reported fields: Progression-free Survival (PFS) as Determined by the Investigator(Median) = 9.89 months (95% Confidence Interval, 8.71 - 11.89); Progression-free Survival (PFS) as Determined by the Investigator(Median) = 8.31 months (95% Confidence Interval, 7.13 - 9.59); Progression-free Survival (PFS) as Determined by the Investigator(Median): Hazard Ratio (HR) = 1.27(95% CI, 1.02 - 1.57), P-Value = 0.9912; P-Value = 0.0176

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tiragolumab/Atezolizumab addresses PD-L1 positive Solid Tumors, Recurrent Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 148 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PDL1 x TIGIT records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-26	CStone Pharma joins hands with Arrotex to commercialise Sugemalimab across Australia and New Zealand	Approved	Financial terms not disclosed
2026-02-18	BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License	Not disclosed	Financial terms not disclosed
2026-01-06	Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco	Phase 1/2	US$50.0M upfront; US$2,000.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Treatment with Anti-tigit antibodies and PD-1 axis binding antagonists”. The milestone feed surfaced a patent-application signal described as “Dosing for treatment with Anti-tigit and Anti-PD-l1 antagonist antibodies”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO